Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | HEXA | P06865 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870325 | 1.00 | CSNK1A1 (0.46) | CSNK1A1CLK4ADORA2AADORA1PDPK1 | |
| SCHEMBL977078 | 0.81 | CSNK1A1 (0.48) | CSNK1A1CLK4ADORA2AADORA1PDPK1 | |
| SCHEMBL29870187 | 0.81 | CSNK1A1 (0.48) | CSNK1A1CLK4ADORA2AADORA1PDPK1 | |
| SCHEMBL12922500 | 0.69 | LMNA (0.43) | ADORA2AADORA1DHFRHEXAHEXB | |
| SCHEMBL8335012 | 0.66 | ESR1 (0.70) | ESR1ESR2TAAR1 | |
| SCHEMBL430941 | 0.66 | ESR1 (0.70) | ESR1ESR2TAAR1 | |
| SCHEMBL11519002 | 0.63 | ESR1 (0.67) | ESR1ESR2TAAR1 | |
| SCHEMBL5887915 | 0.63 | ESR1 (0.75) | ESR1ESR2TAAR1 | |
| Hydrochloric Acid SCHEMBL16859717 | 0.63 | ESR1 (0.67) | ESR1ESR2TAAR1 | |
| SCHEMBL204220 | 0.63 | ESR1 (0.60) | ESR1ESR2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107921046-B | Triazine derivatives as interferon-gamma inhibitors | 格林威治大学 | 2022-10-14 | — | — | CN | claimed |
| EP-3307273-B1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | UNIV GREENWICH (GB) | 2020-12-09 | — | — | EP | claimed |
| US-10576086-B2 | Triazine derivatives as interferon-gamma inhibitors | UNIVERSITY OF GREENWICH (GB) | 2020-03-03 | — | — | US | claimed |
| US-20180169105-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | UNIVERSITY OF GREENWICH (GB) | 2018-06-21 | — | — | US | claimed |
| EP-2229371-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2015-12-23 | — | — | EP | claimed |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | US | claimed |
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| EP-3307273-B1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | UNIV GREENWICH (GB) | 2020-12-09 | — | — | EP | disclosed |
| US-10576086-B2 | Triazine derivatives as interferon-gamma inhibitors | UNIVERSITY OF GREENWICH (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20180169105-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | UNIVERSITY OF GREENWICH (GB) | 2018-06-21 | — | — | US | disclosed |
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | disclosed |
| US-9422253-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2016-08-23 | — | — | US | disclosed |
| EP-3002280-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-2229371-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-20140155403-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2014-06-05 | — | — | US | disclosed |
| CN-101918378-B | Cyclic azide and sodium diazoxide channel blockers | UNIV GREENWICH | 2013-12-04 | — | — | CN | disclosed |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2229371-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009090431-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155403-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | CSNK1A1 719/4885CLK4 1935/4885ADORA2A 396/4885 |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | CACNA1E, SCN2B, SCN3A | CSNK1A1 4578/4885CLK4 4586/4885ADORA2A 806/4885 |
| US-10576086-B2 | Triazine derivatives as interferon-gamma inhibitors | IFNG, IFNAR1, IRF3 | CSNK1A1 599/4885CLK4 3082/4885ADORA2A 3674/4885 |
| US-20180169105-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | IFNG, IFNAR1, IRF3 | CSNK1A1 599/4885CLK4 3082/4885ADORA2A 3674/4885 |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | CSNK1A1 802/4885CLK4 1921/4885ADORA2A 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.